Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Unknown unknown|
|Therapy||Fluorouracil + Irinotecan + Leucovorin + Ramucirumab|
|Indication/Tumor Type||colorectal cancer|
|Response Type||not applicable|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colorectal cancer||not applicable||Fluorouracil + Irinotecan + Leucovorin + Ramucirumab||FDA approved||Actionable||In a Phase III trial (RAISE) that supported FDA approval, treatment with a combination of Cyramza (ramucirumab) and the FOLFIRI chemotherapy regimen improved median overall survival (13.3 vs 11.7 mo, HR=0.844, p=0.0219) in patients with metastatic colorectal cancer (PMID: 25877855; NCT01183780).||25877855 detail...|
|PubMed Id||Reference Title||Details|
|(25877855)||Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.||Full reference...|
|Cyramza (ramucirumab) FDA Drug Label||Full reference...|